John Hardy, Editorial Board member of the soon-to-be launched Alzheimer’s Research & Therapy, has been elected to the Fellowship of the Royal Society for his exceptional contribution to science.  Professor Hardy, UCL Institute of Neurology, is one of the most highly cited authors in Alzheimer’s disease research, with more than 23,000 citations between January 1985 to April 2008.

His research interests are in the genetic analysis of disease, specifically Alzheimer’s disease and other dementias. He has had a focus on investigating tau proteins, which accumulate in abnormal folds in patients with Alzheimer’s.

Professor Hardy is a founding member of the Alzheimer’s Research & Therapy Editorial Board.  The journal aims to be the major forum for translational research into Alzheimer’s disease. An international open access journal, Alzheimer’s Research & Therapy will publish basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. Although the journal’s primary focus is Alzheimer’s dementia, the scope will encompass other neurodegenerative disease.

Congratulations to Professor Hardy from all at BioMed Central.

Frances Mulvany
In-house Editor, Alzheimer’s Research & Therapy